Landmark Vaccines, Ltd.
Landmark Vaccines Limited is a vaccine developer based at Loughborough University Science and Enterprise Park. The company develops next-generation vaccine and immune‑therapy platforms combining transdermal delivery (microneedle-based) and cell-penetrating transfection methods with sub-unit and nucleic acid vaccine modalities. Activities include pre-clinical R&D, formulation for thermostable and cold-chain‑independent deployment, and GMP-aligned manufacturing and release testing supported via a GMP-licensed partner facility.
Industries
N/A
Services
Pre-clinical R&D and partner collaborations
Collaborative pre-clinical research services including antigen design, formulation development, and in vivo evaluation performed with academic and clinical partners.
GMP-aligned manufacturing and clinical trial material production
Manufacturing support leveraging GMP-licensed partner facilities for aseptic preparation, liquid and solid-state formulation, filling, and release testing to produce clinical trial material.
Delivery platform development (microneedle and transfection-enhanced systems)
Development of integrated delivery platforms combining microneedle transdermal formats and transfection-enhancement methods to enable targeted skin delivery of vaccines and immunotherapies.
Formulation and thermostability development
Formulation development services focused on producing thermostable vaccine presentations suitable for distribution without strict cold-chain requirements.
Pre-clinical R&D and partner collaborations
Collaborative pre-clinical research services including antigen design, formulation development, and in vivo evaluation performed with academic and clinical partners.
GMP-aligned manufacturing and clinical trial material production
Manufacturing support leveraging GMP-licensed partner facilities for aseptic preparation, liquid and solid-state formulation, filling, and release testing to produce clinical trial material.
Delivery platform development (microneedle and transfection-enhanced systems)
Development of integrated delivery platforms combining microneedle transdermal formats and transfection-enhancement methods to enable targeted skin delivery of vaccines and immunotherapies.
Formulation and thermostability development
Formulation development services focused on producing thermostable vaccine presentations suitable for distribution without strict cold-chain requirements.
Expertise Areas
- Transdermal vaccine delivery
- Nucleic acid vaccine development (mRNA/DNA)
- Subunit vaccine formulation
- Thermostable vaccine formulation and stabilization
Key Technologies
- Microneedle transdermal delivery
- Cell-penetrating transfection methods
- mRNA platforms
- DNA vaccine platforms